pifithrin has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cadet, JL; Cutler, RG; Duan, W; Greig, NH; Guo, Z; Ladenheim, B; Mattson, MP; Oyler, J; Yu, QS; Zhu, X | 1 |
| Joshi, SD; Karunakaran, S; Meka, DP; Mishra, M; Ravindranath, V; Saeed, U; Seth, P; Valli, RK | 1 |
2 other study(ies) available for pifithrin and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Benzothiazoles; Dopamine; Dopamine Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Thiazoles; Toluene; Tumor Suppressor Protein p53 | 2002 |
Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Benzothiazoles; Brain; Cells, Cultured; Disease Models, Animal; Dopamine; Enzyme Activation; Enzyme Inhibitors; Fetus; Humans; Imidazoles; Male; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neurons; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Protein Transport; Pyrimidines; Stem Cells; Substantia Nigra; Time Factors; Toluene; Tumor Suppressor Protein p53; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |